Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $395,000 (up 359.3% year over year) with net income of −$23M.
Q3 2026 key financials · XBRL
- Revenue
- $395,000
- +359.3% YoY · −9.0% QoQ
- Net income
- −$23M
- −18.9% YoY · +6.5% QoQ
- Operating margin
- -6149.9%
- EPS (diluted)
- −$0.32
- −14.3% YoY · +11.1% QoQ
Source: XBRL data from the PULSE BIOSCIENCES, INC. (PLSE) Q3 2026 10-Q on SEC EDGAR. USD.
PULSE BIOSCIENCES, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0.4M, up $0.3M YoY from $0.1M, entirely from limited Vybrance sales
- Operating margin not disclosed; operating loss $24.3M vs $20.4M YoY
- Vybrance best-performing product line, revenue $0.4M versus $0.1M YoY
- Cash, equivalents and marketable securities $189.2M; operating cash use $48.6M for nine months
- Management expects additional losses, plans near-term capital raising, cites financing access and market conditions as headwinds
Risk Factors
- New AI compliance risk triggered by expanded internal use of generative AI and machine learning, including EU AI Act and evolving FDA requirements
- Regulatory review delays heightened by FDA workforce reductions, voluntary departures, and policy uncertainty since January 2025
- Near-term adoption risk: surgeons have been slow to adopt the Vybrance System due to limited clinical data and reimbursement uncertainty
- Liquidity risk: additional capital required, with armed conflicts and tariffs potentially restricting financing availability or increasing dilution
- Cybersecurity risk: limited resources and no redundant information technology across all systems increase vulnerability to disruptive incidents
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PULSE BIOSCIENCES, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.